SuperGen reports preliminary rubitecan data

SUPG said preliminary results from a U.S. Phase II trial showed that 23 of 54 patients (43 percent) treated with its rubitecan oral 9-nitrocamptothecin topoisomerase I inhibitor had a complete respons...